Abstract
Summary
The consensus views on osteoporosis in men are reported.
Introduction
A workshop was convened within a meeting on osteoporosis in men to identify areas of consensus amongst the panel (the authors) and the participants of the meeting.
Methods
A public debate with an expert panel on preselected topics was conducted.
Results and Conclusions
Consensus views were reached on diagnostic criteria and several aspects on the pathophysiology and treatment of osteoporosis in men.
Similar content being viewed by others
References
World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical report series 843. WHO, Geneva
Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:17–1141
Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ, Khaltaev N (2008) A reference standard for the description of osteoporosis. Bone 42:467–475
Kanis JA, Glüer CC, for the Committee of Scientific Advisors, International Osteoporosis Foundation (2000) An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporos Int 11:192–202
Melton LJ III, Atkinson EJ, O’Connor MK, O’Fallon WM, Riggs BL (1998) Bone density and fracture risk in men. J Bone Miner Res 13:1915–1923
Melton LJ III, Orwoll ES, Wasnich RD (2001) Does bone density predict fractures comparably in men and women? Osteoporos Int 12:707–709
Cummings SR, Cawthon PM, Ensrud KE et al (2006) BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women. J Bone Miner Res 21:1550–6
Johnell O, Kanis JA, Oden A et al (2005) Predictive value of bone mineral density for hip and other fractures. J Bone Miner Res 20:1185–1194
Kanis JA, Johnell O, Oden A, De Laet C, Mellstrom D (2001) Diagnosis of osteoporosis and fracture threshold in men. Calcif Tissue Int 69:218–221
Orwoll E (2000) Assessing bone density in men. J Bone Miner Res 15:1867–1870
Selby PL, Davies M, Adams JE (2000) Do men and women fracture bones at similar bone densities. Osteoporos Int 11:153–157
Lunt M, Felsenberg D, Reeve J et al (1997) Bone density variation and its effects on risk of vertebral deformity in men and women studied in thirteen European centers: the EVOS Study. J Bone Miner Res 12:1883–94
Nguyen T, Sambrook P, Kelly P et al (1993) Prediction of osteoporotic fractures by postural instability and bone density. Br Med J 307:1111–1115
DeLaet CED, van Hout BA, Burger H, Hoffman A, Pols HAP (1997) Bone density and risk of hip fracture in men and women: cross sectional analysis. Brit Med J 315:221–225
DeLaet CEDH, Van Hout BA, Burger H, Hofman A, Weel AEAM, Pols HAP (1998) Hip fracture prediction in elderly men and women: validation in the Rotterdam Study. J Bone Miner Res 13:1587–1593
Wasnich RD, Davis JW, Ross PD (1994) Spine fracture risk is predicted by non spine fractures. Osteoporos Int 4:1–5
Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A (2000) Risk of hip fracture according to World Health Organization criteria for osteoporosis and osteopenia. Bone 27:585–590
Currey JD (2002) Bones: structure and mechanics. Princeton University Press, Princeton, pp 1–380
Parfitt AM (2008) Skeletal heterogeneity and the purposes of bone remodeling: Implications for the understanding of osteoporosis. In: Marcus R, Feldman D, Nelson DA, Rosen CJ (eds) Osteoporosis. Academic, San Diego, pp 71–89
Seeman E, Delmas PD (2006) Bone quality—the material and structural basis of bone strength and fragility. N Engl J Med 354:2250–61
Lips P, Courpron P, Meunier PJ (1978) Mean wall thickness of trabecular bone packets in the human iliac crest: changes with age. Calcif Tissue Res 26:13–7
Garnero P, Sorney-Rendu E, Duboeuf F, Delmas PD (1999) Markers of bone turnover predict postmenopausal bone loss over 4 years: the OFELY study. J Bone Miner Res 14:1614–21
Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS (2004) Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Oncol 22:2546–63
Balena R, Shih M-S, Parfitt AM (1992) Bone resorption and formation on the periosteal envelope of the ilium: a histomorphometric study in healthy women. J Bone Miner Res 7:1475–1482
Aaron JE, Makins NB, Sagreiya K (1987) The microanatomy of trabecular bone loss in normal aging men and women. Clin Orthop Relat Res 215:260–71
Zebaze R, Ghasem-Zadeh A, Bohte A et al (2010) Intracortical remodeling and porosity: rational targets for fracture prevention. Lancet 375:1729–36
Burghardt AJ, Buie HR, Laib A, Majumdar S, Boyd SK (2010) Rreproducibility of direct quantitative measures of cortical bone microarchitecture of the distal radius and tibia by HR-pQCT. Bone 47:519–28
Burghardt AJ, Kazakia GJ, RamachandranS LTM, Majumdar S (2010) Age- and gender-related differences in the geometric properties and biomechanical significance of intracortical porosity in the distal radius and tibia. J Bone Miner Res 25:983–93
Bass S, Delmas PD, Pearce G, Hendrich E, Tabensky A, Seeman E (1999) The differing tempo of growth in bone size, mass and density in girls is region-specific. J Clin Invest 104:795–804
Duan Y, Wang XF, Evans A, Seeman E (2005) Structural and biomechanical basis of racial and sex differences in vertebral fragility in Chinese and Caucasians. Bone 36:987–98
Riggs BL, Melton LJ III, Robb RA et al (2004) A population-based study of age and sex differences in bone volumetric density, size, geometry and structure at different skeletal sites. J Bone Miner Res 19:1945–54
Seeman E (2003) Periosteal bone formation—a neglected determinant of bone strength. N Engl J Med 349:320–3
Ural A, Vashishth D (2006) Interactions between microstructural and geometrical adaptation in human cortical bone. J Orthop Res 24:1489–98
Nalla RK, Kruzic JJ, Kinney JH et al (2010) Role of microstructure in the aging-related deterioration of the toughness of human cortical bone. Mater Sci Eng, C 26:1251–1260
Yeni YN, Brown CU, Wang Z, Norman TL (1997) The influence of bone morphology on fracture toughness of the human femur and tibia. Bone 21:453–9
Currey JD (1988) The effect of porosity and mineral content on the Young’s modulus of elasticity of compact bone. J Biomech 21:131–139
Ciarelli TE, Fyhrie DP, Parfitt AM (2003) Effects of vertebral bone fragility and bone formation rate on the mineralization levels of cancellous bone from white females. Bone 32:311–5
Qiu S, Rao DS, Fyhrie DP, Palnitkar S, Parfitt AM (2005) The morphological association between microcracks and osteocyte lacunae in human cortical bone. Bone 37:10–15
Zebaze R, Seeman E, Ghasem-Zadeh A et al (2010) Analysis system and method. Australian Provisional Patent No. 2009904407
Saito M, Marumo K (2010) Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int 21:195–214
Tang SY, Zeenath U, Vashishth D (2007) Effects of non-enzymatic glycation on cancellous bone fragility. Bone 40:1144–51
Duan Y, Seeman E, Turner CH (2001) The biomechanical basis of vertebral body fragility in men and women. J Bone Miner Res 16:2276–2283
Orwoll E, Ettinger M, Weiss S et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604–610
Ho YV, Frauman AG, Thomson W, Seeman E (2000) Effects of alendronate on bone density in men with primary and secondary osteoporosis. Osteoporos Int 11:98–101
Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP (2000) Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85:3069–3076
Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Eng J Med 344:1434–1441
Orwoll ES, Scheele WH, Paul S et al (2003) The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9–17
Gonnell S, Cepoliano C, Montagnani A et al (2003) Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study. Calcif Tissue Int 73:133–159
Drake WM, Kendler DL, Rosen CJ, Orwoll ES (2003) An investigation of the predictors of bone mineral density and response to therapy with alendronate in osteoporotic men. J Clin Endocrinol Metab 88:5759–5765
Miller PD, Schnitzer T, Emkey R et al (2004) Weekly oral alendronic acid in male osteoporosis. Clin Drug Invest 24l:333–341
Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD (2009) Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 24:719–725
Ringe JD, Farahmand P, Faber K, Dorst A (2009) Sustained efficacy of risedronate in men with primary and secondary osteporoosis: results of a 2-year study. Rheumatol Int 29:311–315
Orwoll ES, Miller PD, Adachi JD et al (2010) Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 25:2239–2250
Orwoll ES, Binkley NC, Lweiecki EM, Gruntmanis U, Fries MA, Dasic G (2010) Efficacy and safety of monthly ibandronate in men with low bone density. Bone 46:970–976
Boonen S, Kaufman JM, Reginster J-Y et al (2011) Antifracture efficacy and safety of once-yearly zoledronic acid 5 mg in men with osteoporosis: a prospective, randomised, controlled trial. Osteoporos Int 22 (Suppl 1):S180
Smith MR, Egerdie B, Hernández Toriz N, Denosumab HALT Prostate Cancer Study Group et al (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:745–55
World Health Organization (1998) Guidelines for preclinical evaluation and clinical trials in osteoporosis. WHO, Geneve
Lang T, Cauley JA, Tylavsky F, BauerD CS, Harris TB (2010) Computed tomographic measurements of thigh muscle cross-sectional area and attenuation coefficient predict hip fracture: The health, aging, and body composition study. J Bone Miner Res 25:513–519
Lewis CE, Ewing SK, Taylor BC et al (2007) Predictors of non-spine fracture in elderly men: the MrOS study. J Bone Miner Res 22:211–219
Cummings SR, Nevitt MC, Browner WS et al (1995) Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 332:767–773
Cawthon PM, Fullman RL, Marshall L et al (2008) Physical performance and risk of hip fractures in older men. J Bone Miner Res 23:1037–44
Michael YL, Whitlock EP, Lin JS, Fu R, O'Connor EA, Gold R (2010) Primary care-relevant interventions to prevent falling in older adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 153:815–825
Bischoff-Ferrari HA, Orav EJ, Dawson-Hughes B (2006) Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial. Arch Intern Med 166:424–430
McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340
De Laet C, Kanis JA, Oden A et al (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16:1330–8
Flegal KM, Carroll MD, Ogden CL et al (2010) Prevalence and trends in obesity among US adults, 1999–2008. JAMA 303:235–41
Sundquist J, Johnansson S-E, Sundquist K (2010) Levelling off of prevalence of obesity in the adult population of Sweden between 2000/01 and 2004/05. BMC Public Health 2010:10
Nielson CM, Marshall LM, Adams AL et al (2010) BMI and fracture risk in older men: the osteoporotic fractures in men (MrOS) study. J Bone Miner Res 26(3):496–502
Freitas SS, Barrett-Connor E, Ensrud KE et al (2008) Rate and circumstances of clinical vertebral fractures in older men. Osteoporos Int 19:615–623
Khosla S, Amin S, Orwoll E (2008) Osteoporosis in men. Endocr Rev 29:441–464
Peacock M, Koller DL, Lai D, Hui S, Foroud T, Econs MJ (2009) Bone mineral density variation in men is influenced by sex-specific and non sex-specific quantitative trait loci. Bone 45:443–448
Khosla S, Melton LJ III, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL (1998) Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 83:2266–2274
Rapado A, Hawkins F, Sobrinho L et al (1999) Bone mineral density and androgen levels in elderly males. Calcif Tissue Int 65:417–21
Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R, Khosla S (2000) Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 106:1553–1560
Leder BZ, LeBlanc KM, Schoenfeld DA, Eastell R, Finkelstein JS (2003) Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab 88:204–210
Khosla S, Melton LJ, Atkinson EJ, O'Fallon WM (2001) Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 86:3555–3561
Van Pottelbergh I, Goemaere S, Kaufman JM (2003) Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age. J Clin Endocrinol Metab 88:3075–3081
Lapauw B, Taes Y, Goemaere S, Toye K, Zmierczak H-G, Kaufman J-M (2009) Anthropometric and skeletal phenotype in men with idiopathic osteoporosis and their sons is consistent with deficient estrogen action during maturation. J Clin Endocrinol Metab 94:4300–4308
Khosla S, Melton LJ, Riggs BL (2002) Estrogen and the male skeleton. J Clin Endocrinol Metab 87:1443–1450
Mellstrom D, Vandenput L, Mallmim H et al (2008) Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res 23:1552–1560
Riggs BL, Melton LJ (1986) Medical progress series: involutional osteoporosis. N Engl J Med 314:1676–1686
Smith MR (2007) Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diab Obes 14:247–254
Lowe H, Shane E (2008) Osteoporosis associated with illnesses and medications. In: Marcus R, Feldman D, Nelson DA, Rosen CJ (eds) Osteoporosis. Elsevier, San Diego, pp 1283–1314
Stepan JJ, Lachman M, Zverina J, Pacovsky V, Baylink DJ (1989) Castrated men exhibit bone loss—effect of calcitonin treatment on biochemical indexes of bone remodeling. J Clin Endocrinol Metab 69:523–527
Stoch SA, Parker RA, Chen LP, Bubley G, KO YJ, Vincelette A, Greenspan SL (2001) Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 86:2787–2791
Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM (2002) Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 87:3656–3661
Shahinian VB, Kuo Y, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154–164
Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C (2004) Androgens and bone. Endocr Rev 25:389–425
Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM (2006) Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 91:1995–2010
Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E (1997) Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 82:2386–2390
Crawford BA, Liu PY, Kean MT, Bleasel JF, Handelsman DJ (2003) Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 88:3167–3176
Smith MR, Fallon MA, Lee H, Finkelstein JS (2004) Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 89:3841–3846
Michaelson MD, Kaufman DS, Lee H et al (2007) Randomized controlled trial of annual zoledronic acidto prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostatz cancer. J Clin Oncol 25:1038–1042
Greenspan SL, Nelson JB, Trump DL, Resnick NM (2007) Effect of once weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer. Ann Intern Med 146:416–424
Kaufman JM, Vermeulen A (2005) The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 26:833–876
Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A (2005) Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta analysis. Clin Endocrinol (oxf) 63:280–293
Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh I, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF, Haddad JG Jr, Strom BL (1999) Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84:1966–1972
Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL (2004) Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 89:503–510
Fernandez-Balsells MM, Murad MH, Lane M et al (2010) Adverse efects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 95:2560–2575
Basaria S, Coviello AD, Travison TG et al (2010) Adverse events associated with testosterone administration. N Engl J Med 363:109–122
Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC (2008) Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 159:507–14
Competing interests
JAK has nothing to declare for FRAX and the context of this paper but has numerous ad hoc consultancies for governmental, non-governmental agencies and the pharmaceutical industry. GB and ES have no competing interests with regard to this manuscript. SK is a member of the advisory board for Amgen. JPB is a consultant for Amgen.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kanis, J.A., Bianchi, G., Bilezikian, J.P. et al. Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int 22, 2789–2798 (2011). https://doi.org/10.1007/s00198-011-1632-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-011-1632-z